… , vedolizumab maintenance therapy … vedolizumab therapy at a dose of 300 mg every 4
weeks through week 54 in patients who did not have a sufficient response to vedolizumab therapy …

… In patients who did not have a response to vedolizumab therapy at weeks 10 to 14, the
treating physician was free to optimize vedolizumab therapy at a dose of 300 mg every 4 weeks …

… track closely with luminal disease. In this case series, vedolizumab therapy was effective for
… , but did not provide sustained benefit for the treatment of PG in CD. Notably, most of these …

… In conclusion, the final analysis of GEMINI LTS comprehensively demonstrates that
vedolizumab therapy has a safety and tolerability profile suitable for long-term treatment of patients …

… We identified six eligible Crohn’s disease and seven eligible ulcerative colitis trials that …
per disease cohort to infliximab or vedolizumab. In the Crohn’s disease and ulcerative colitis …

… in patients with inflammatory bowel disease. We conducted integrated induction and
maintenance trials of vedolizumab in patients with moderately to severely active Crohn's disease. …

… Safety profile of vedolizumab … databases with the key words (vedolizumab OR MLN002)
AND (inflammatory bowel disease OR ulcerative colitis OR Crohn) AND (safety OR pregnan* OR …

… of vedolizumab therapy at a dose of 300 mg every 4 weeks in patients who did not have
a sufficient response to vedolizumab therapy and de-escalation of vedolizumab therapy to a …

… Ulcerative colitis is a chronic inflammatory bowel disease … Of particular relevance was the
benefit of vedolizumab therapy … of the patients who received vedolizumab every 8 weeks and …

… vedolizumab therapy. Among adult UC subjects demonstrating clinical response from
vedolizumab … 54 weeks of therapy, 80% of subjects remained on vedolizumab therapy. Outcomes …